RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo
Columvi is one of two bispecific antibody drugs that Roche recently introduced in the blood cancer space.
The other Roche CD20xCD3 bispecific, Lunsumio, was approved in late 2022 to treat relapsed or refractory follicular lymphoma.
https://www.fiercepharma.com/pharma/covid-windfall-rear-mirror-roche-starts-flesh-out-blood-cancer-ambition
Like Roche, Pfizer is becoming increasingly involved with bispecifics.
The FDA’s Accelerated Approval of Pfizers bispecific in relapsed or refractory multiple myeloma (RRMM) patients, was supported by data from the Phase II MagnetisMM-3 study, which had an overall response rate (ORR) of 58%, in which around 82% patients maintained this response through at least nine months - so one would think that anything around a 40-60% ORR result should give ONCY an AA in mPDAC since metastatic pancreatic cancer is a rare disease with an unmet treatment need.
https://www.biospace.com/article/pfizer-bispecific-drug-wins-fda-accelerated-approval-for-multiple-myeloma/